Consensus revenue is projected at $0.00 million as the company remains in its pre-commercial development phase, with EPS expected at -$0.27 against a current stock price of $3.07 and an average analyst target of $19.67. The primary story for investors is the clinical progression and regulatory path for NS002, the company’s intranasal epinephrine powder candidate for treating anaphylaxis.
Recent momentum has been driven by positive preclinical data for NS003, an intranasal formulation for nausea, and a successful $15 million private placement that bolstered the firm's capital position. Analysts are specifically monitoring for updates on the initiation of first-in-human pharmacokinetic studies scheduled for the third quarter of 2026.